PBE

Invesco Dynamic Biotechnology & Genome ETF

Down$52.46
$-0.55
(-1.04%)
As of 12:00:00 AM EDT | 7/19/19  |  Market Closed

PBE Trading Data

Open

$52.99

Low Price

$52.46

High Price

$52.99

Previous Last Price

$53.01

Bid Size

$0 X 0

Ask Size

$0 X 0

PBE Portfolio Data

AUM

$243,800,000

Shares

4,600

PE Ratio

140.05

Price / Book Ratio

4.32

Expense Ratio

0.59

Net Asset Value

$53.00

Volume

Volume

2,700

Avg. Volume (YDT)

20,501

Dollar Volume

$114,170

Weekly Avg. Volume

7,680

Monthly Avg. Volume

16,545

Quarterly Avg. Volume

22,894

PBE Fund Description

The Invesco Dynamic Biotechnology and Genome ETF is based on the Dynamic Biotech and Genome Intellidex Index. The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Index. The Intellidex Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value. The Underlying Intellidex Index is comprised of common stocks of 30 US biotechnology and genome companies. These are companies that are principally engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research. The Fund and the Index are rebalanced and reconstituted quarterly in February, May, August and November.

PBE Chart

PBE Summary

Fund Family

Invesco

Tracks This Index

Invesco Dynamic Biotechnology & Genome ETF

Inception Date

2005-06-23

Asset Class

Equity

Asset Class Size

Biotech

PBE Classification

Region (General)

North America

Region (Specific)

US

Sector

Health Care

Equity Index

Leveraged Family

PBE Holdings

Top 10 Holdings

Bio-Techne Corp (TECH)
5.1%
Ionis Pharmaceuticals Inc (IONS)
5.04%
Amgen Inc (AMGN)
4.92%
Vertex Pharmaceuticals Inc (VRTX)
4.85%
Biogen Inc (BIIB)
4.81%
Incyte Corp (INCY)
4.79%
Regeneron Pharmaceuticals Inc (REGN)
4.56%
Celgene Corp (CELG)
4.46%
Array BioPharma Inc (ARRY)
4.31%
FibroGen Inc (FGEN)
3.33%

Total PBE Holdings

Total Holdings: 31

Bio-Techne Corp (TECH)
5.1%
Ionis Pharmaceuticals Inc (IONS)
5.04%
Amgen Inc (AMGN)
4.92%
Vertex Pharmaceuticals Inc (VRTX)
4.85%
Biogen Inc (BIIB)
4.81%
Incyte Corp (INCY)
4.79%
Regeneron Pharmaceuticals Inc (REGN)
4.56%
Celgene Corp (CELG)
4.46%
Array BioPharma Inc (ARRY)
4.31%
FibroGen Inc (FGEN)
3.33%
Blueprint Medicines Corp (BPMC)
3.18%
Repligen Corp (RGEN)
3.09%
Catalent Inc (CTLT)
3.02%
Veracyte Inc (VCYT)
2.98%
Arena Pharmaceuticals Inc (ARNA)
2.92%
Halozyme Therapeutics Inc (HALO)
2.82%
Cardiovascular Systems Inc (CSII)
2.82%
Exelixis Inc (EXEL)
2.8%
Alkermes PLC (ALKS)
2.79%
Myriad Genetics Inc (MYGN)
2.77%
Voyager Therapeutics Inc (VYGR)
2.77%
Emergent BioSolutions Inc (EBS)
2.72%
Genomic Health Inc (GHDX)
2.68%
Madrigal Pharmaceuticals Inc (MDGL)
2.61%
Nektar Therapeutics (NKTR)
2.52%
Enanta Pharmaceuticals Inc (ENTA)
2.31%
Esperion Therapeutics Inc (ESPR)
2.3%
Vanda Pharmaceuticals Inc (VNDA)
2.26%
Spark Therapeutics Inc (ONCE)
2.25%
Fluidigm Corp (FLDM)
2.24%
PowerShares Dynamic Biotechnology & Genome Portfolio (PBE)
0%

PBE Technicals

Alpha

-3.3

Beta

1.46

Leverage

Long

Standard Deviation

3.66

PBE Dividends

Dividend Date

2018-09-24

Latest Dividend

0.002

Annual Dividend

0

Annual Dividend Rate

0

Annual Dividend Yield

1.0E-5

PBE Performance

YTD Return

11.46%

1 Year Return

-11.95%

3 Year Return

31.65%

5 Year Return

21.02%

10 Year Return

226.06%

PBE Related Articles